Search

Your search keyword '"Dragani, Tommaso A"' showing total 17 results
Start Over Author "Dragani, Tommaso A" Journal international journal of cancer
17 results on '"Dragani, Tommaso A"'

1. Germline polymorphisms and survival of lung adenocarcinoma patients: A genome-wide study in two European patient series

Author

Galvan, Antonella, Colombo, Francesca, Frullanti, Elisa, Dassano, Alice, Noci, Sara, Wang, Yufei, Eisen, Timothy, Matakidou, Athena, Tomasello, Luisa, Vezzalini, Marzia, Sorio, Claudio, Dugo, Matteo, Ambrogi, Federico, Iacobucci, Ilaria, Martinelli, Giovanni, Incarbone, Matteo, Alloisio, Marco, Nosotti, Mario, Tosi, Davide, Santambrogio, Luigi, Pelosi, Giuseppe, Pastorino, Ugo, Houlston, Richard S., and Dragani, Tommaso A.

Published
2015
Full Text
View/download PDF

7. Germline polymorphisms and survival of lung adenocarcinoma patients: A genome‐wide study in two European patient series

Author

Galvan, Antonella, primary, Colombo, Francesca, additional, Frullanti, Elisa, additional, Dassano, Alice, additional, Noci, Sara, additional, Wang, Yufei, additional, Eisen, Timothy, additional, Matakidou, Athena, additional, Tomasello, Luisa, additional, Vezzalini, Marzia, additional, Sorio, Claudio, additional, Dugo, Matteo, additional, Ambrogi, Federico, additional, Iacobucci, Ilaria, additional, Martinelli, Giovanni, additional, Incarbone, Matteo, additional, Alloisio, Marco, additional, Nosotti, Mario, additional, Tosi, Davide, additional, Santambrogio, Luigi, additional, Pelosi, Giuseppe, additional, Pastorino, Ugo, additional, Houlston, Richard S., additional, and Dragani, Tommaso A., additional

Published
2014
Full Text
View/download PDF

8. A polygenic model with common variants may predict lung adenocarcinoma risk in humans

Author

Galvan, Antonella, primary, Falvella, Felicia S., additional, Spinola, Monica, additional, Frullanti, Elisa, additional, Leoni, Vera P., additional, Noci, Sara, additional, Alonso, Maria R., additional, Zolin, Anna, additional, Spada, Elena, additional, Milani, Silvano, additional, Pastorino, Ugo, additional, Incarbone, Matteo, additional, Santambrogio, Luigi, additional, Neira, Anna Gonzalez, additional, and Dragani, Tommaso A., additional

Published
2008
Full Text
View/download PDF

11. Inhibition of both skin and lung tumorigenesis by Car‐R mouse‐derived cancer modifier loci

Author

Saran, Anna, primary, Zaffaroni, Daniela, additional, Pazzaglia, Simonetta, additional, Peissel, Bernard, additional, Galbiati, Federica, additional, Spinola, Monica, additional, Manenti, Giacomo, additional, Zanesi, Nicola, additional, Rebessi, Simonetta, additional, Mancuso, Maria Teresa, additional, Covelli, Vincenzo, additional, and Dragani, Tommaso A., additional

Published
2001
Full Text
View/download PDF

12. Linkage disequilibrium pattern in the L-myc gene in Italian and Japanese non-small-cell lung-cancer patients

Author

Spinola, Monica, primary, Nomoto, Tomoko, additional, Manenti, Giacomo, additional, Falvella, F. Stefania, additional, Brega Massone, Pier Paolo, additional, Conti, Barbara, additional, Cataldo, Ignazio, additional, Valagussa, Pinuccia, additional, Incarbone, Matteo, additional, Miyamoto, Kazuaki, additional, Ushijima, Toshikazu, additional, and Dragani, Tommaso A., additional

Published
2001
Full Text
View/download PDF

15. Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinoma

Author

Gregorio, Laura De, Manenti, Giacomo, Incarbone, Matteo, Pilotti, Silvana, Pastorino, Ugo, Pierotti, Marco A., and Dragani, Tommaso A.

Abstract

The prognostic values of loss of heterozygosity (LOH) at loci frequently involved in non-small cell lung cancer and of KRAS2 gene mutations were studied in lung adenocarcinoma patients. LOHs were relatively common, ranging from 24% at chromosome 10p to 55% at chromosome 17p13. KRAS2 mutations at codon 12 were present in 26% of cases, were more common in male than in female patients and were associated with a smoking habit. No association between LOH at any site and clinical stage or survival rate was found. On the other hand, we observed a trend between the presence of any type of KRAS2 mutations and poor survival. Analysis of specific KRAS2 mutations showed a strong effect of Asp (GAT) and Val (GTT) mutations, resulting in a very poor survival compared with wild type group, whereas the most common mutation (Cys, TGT) was not associated with prognosis. Our results indicate the importance of specific activating mutations of the KRAS2 gene as genetic markers of clinical outcome for patients with lung adenocarcinoma. Int. J. Cancer (Pred. Oncol.) 79:269–272, 1998.© 1998 Wiley-Liss, Inc.

Published
1998
Full Text
View/download PDF

16. Linkage disequilibrium pattern in the L-<TOGGLE>myc</TOGGLE> gene in Italian and Japanese non-small-cell lung-cancer patients

Author

Spinola, Monica, Nomoto, Tomoko, Manenti, Giacomo, Falvella, F. Stefania, Massone, Pier Paolo Brega, Conti, Barbara, Cataldo, Ignazio, Valagussa, Pinuccia, Incarbone, Matteo, Miyamoto, Kazuaki, Ushijima, Toshikazu, and Dragani, Tommaso A.

Abstract

Italian and Japanese non-small-cell lung-cancer patients were genotyped for an intragenic L-myc EcoRI restriction site polymorphism previously reported to be associated with lung-tumor prognosis in Asian populations but not in Caucasians. Screening of the L-myc sequence in Italian samples allowed identification of 2 additional 3'-UTR SNPs, located 2.3–3.0 kb from the EcoRI polymorphism, but no coding polymorphism was found. No significant association was found between any of the 3 SNPs and lung-tumor prognosis in Italian patients, consistent with the reported difference between Caucasian and Asian populations. Moreover, the newly discovered polymorphisms in the Italian group were not present in Japanese patients. Significant LD between EcoRI and the 2 other SNPs was detected in the Italian population, whereas no significant LD between the 2 3'-UTR markers was detected despite their close proximity (0.7 kb). Thus, the disparate conclusions about the role of L-myc polymorphism in tumor prognosis among different populations may rest in population-specific LD between the functional gene and the L-myc polymorphism. © 2001 Wiley-Liss, Inc.

Published
2001
Full Text
View/download PDF

17. Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas.

Author

Bjaanaes MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M, Pastorino U, Kure E, Børresen-Dale AL, Brustugun OT, and Helland A

Subjects
Adenocarcinoma genetics, Adenocarcinoma mortality, Adenocarcinoma of Lung, Aged, Cohort Studies, DNA Mutational Analysis, Female, Humans, Kaplan-Meier Estimate, Lung Neoplasms genetics, Lung Neoplasms mortality, Male, MicroRNAs metabolism, Middle Aged, Mutation, Oligonucleotide Array Sequence Analysis, Proportional Hazards Models, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins p21(ras), ras Proteins genetics, Adenocarcinoma metabolism, ErbB Receptors genetics, Lung Neoplasms metabolism, MicroRNAs genetics, Transcriptome
Abstract

The findings of mutations and the development of targeted therapies have improved lung cancer management. Still, the prognosis remains poor, and we need to know more about the genetic and epigenetic alterations in lung cancer. MicroRNAs are involved in crucial biological processes like carcinogenesis by regulating gene expression at the post-transcriptional level. In this project, we have studied the microRNA expression of lung adenocarcinomas and corresponding normal lung tissue and correlated the expression with clinical data and EGFR- and KRAS-mutational status. Agilent microarrays have been used, examining microRNA expression in 154 surgically resected lung adenocarcinomas and 20 corresponding normal lung tissue samples. Findings were confirmed by RT-qPCR in the same cohort and in an independent cohort of 103 lung cancer patients. EGFR and KRAS mutation analyses were also performed. 129 microRNAs were significantly differentially expressed in lung adenocarcinomas compared with normal lung tissue, and 17 microRNAs were differentially expressed between EGFR-mutated and EGFR wildtype tumors. We identified microRNAs associated with time to progression. We have identified several aberrantly expressed microRNAs that discriminate lung adenocarcinomas from normal lung tissue, and hence may be potential biomarkers for early detection. We have found microRNAs that are differentially expressed between EGFR-mutated and EGFR wildtype lung adenocarcinomas, suggesting that microRNAs can be used as molecular biomarkers in classification. We hypothesize that microRNA expression can be used as biomarkers for clinical course., (© 2014 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results